Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385419989> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W4385419989 endingPage "25" @default.
- W4385419989 startingPage "18" @default.
- W4385419989 abstract "Lorlatinib is a new third-generation tyrosine kinase (TKI) inhibitor of ALK/ROS1, which has antitumour activity against most of the known mutations of resistance to crizotinib and second-generation TKI, as well as high intracranial efficacy. The safety of lorlatinib was evaluated in a multi-cohort phase I study involving 295 patients receiving the recommended dose of lorlatinib 100 mg once a day. Adverse events of lorlatinib were mainly mild to moderate severity. The most frequent complications – hypercholesterolemia (82.4%), hypertriglyceridemia (60.7%), edema (51.2%), peripheral neuropathy (43.7%) and side effects from the central nervous system (39.7%), were reversible and well controlled by dose modification and concomitant therapy, as evidenced by the low frequency of discontinuation of therapy due to adverse reactions. The majority of patients (81.0%) required the appointment of at least one hypolipidemic drug. When prescribing concomitant therapy, the possibility of drug interaction with lorlatinib, whose metabolism is carried out with the participation of specific CYP450 enzymes, should also be taken into account. Based on the presented results, an expert consensus opinion was developed on the correction of the main adverse reactions, including hyperlipidemia, complications from the central nervous system, weight gain, edema, peripheral neuropathy and others. No new adverse events were reported in the CROWN Phase III study conducted later. Lorlatinib has a characteristic toxicity profile, which must be taken into account for successful long-term targeted therapy while maintaining a good quality of life for patients. In the Russian Federation, the drug is approved for use in a wide clinical practice both for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) in the first line, and after progression to second-generation TKI. The article presents recommendations for the correction of the main adverse events of lorlatinib, as well as their own experience in managing patients." @default.
- W4385419989 created "2023-08-01" @default.
- W4385419989 creator A5035278457 @default.
- W4385419989 creator A5043075117 @default.
- W4385419989 creator A5053168248 @default.
- W4385419989 creator A5077301130 @default.
- W4385419989 creator A5092781173 @default.
- W4385419989 date "2023-07-26" @default.
- W4385419989 modified "2023-10-16" @default.
- W4385419989 title "Safety profile of lorlatinib: correction of adverse events" @default.
- W4385419989 cites W1972661406 @default.
- W4385419989 cites W1974903221 @default.
- W4385419989 cites W2046826638 @default.
- W4385419989 cites W2047207059 @default.
- W4385419989 cites W2065477010 @default.
- W4385419989 cites W2065799563 @default.
- W4385419989 cites W2099530756 @default.
- W4385419989 cites W2113327188 @default.
- W4385419989 cites W2121005606 @default.
- W4385419989 cites W2168106545 @default.
- W4385419989 cites W2208535430 @default.
- W4385419989 cites W2482427906 @default.
- W4385419989 cites W2581996620 @default.
- W4385419989 cites W2610816290 @default.
- W4385419989 cites W2624310346 @default.
- W4385419989 cites W2767072667 @default.
- W4385419989 cites W2784414491 @default.
- W4385419989 cites W2899668190 @default.
- W4385419989 cites W2922836343 @default.
- W4385419989 cites W3101089668 @default.
- W4385419989 cites W4313249535 @default.
- W4385419989 doi "https://doi.org/10.21518/ms2023-239" @default.
- W4385419989 hasPublicationYear "2023" @default.
- W4385419989 type Work @default.
- W4385419989 citedByCount "0" @default.
- W4385419989 crossrefType "journal-article" @default.
- W4385419989 hasAuthorship W4385419989A5035278457 @default.
- W4385419989 hasAuthorship W4385419989A5043075117 @default.
- W4385419989 hasAuthorship W4385419989A5053168248 @default.
- W4385419989 hasAuthorship W4385419989A5077301130 @default.
- W4385419989 hasAuthorship W4385419989A5092781173 @default.
- W4385419989 hasBestOaLocation W43854199891 @default.
- W4385419989 hasConcept C126322002 @default.
- W4385419989 hasConcept C134018914 @default.
- W4385419989 hasConcept C197934379 @default.
- W4385419989 hasConcept C2776919658 @default.
- W4385419989 hasConcept C2778163477 @default.
- W4385419989 hasConcept C2778715236 @default.
- W4385419989 hasConcept C2778913445 @default.
- W4385419989 hasConcept C2779384505 @default.
- W4385419989 hasConcept C2779901536 @default.
- W4385419989 hasConcept C555293320 @default.
- W4385419989 hasConcept C71924100 @default.
- W4385419989 hasConcept C90924648 @default.
- W4385419989 hasConceptScore W4385419989C126322002 @default.
- W4385419989 hasConceptScore W4385419989C134018914 @default.
- W4385419989 hasConceptScore W4385419989C197934379 @default.
- W4385419989 hasConceptScore W4385419989C2776919658 @default.
- W4385419989 hasConceptScore W4385419989C2778163477 @default.
- W4385419989 hasConceptScore W4385419989C2778715236 @default.
- W4385419989 hasConceptScore W4385419989C2778913445 @default.
- W4385419989 hasConceptScore W4385419989C2779384505 @default.
- W4385419989 hasConceptScore W4385419989C2779901536 @default.
- W4385419989 hasConceptScore W4385419989C555293320 @default.
- W4385419989 hasConceptScore W4385419989C71924100 @default.
- W4385419989 hasConceptScore W4385419989C90924648 @default.
- W4385419989 hasIssue "11" @default.
- W4385419989 hasLocation W43854199891 @default.
- W4385419989 hasOpenAccess W4385419989 @default.
- W4385419989 hasPrimaryLocation W43854199891 @default.
- W4385419989 hasRelatedWork W1984309643 @default.
- W4385419989 hasRelatedWork W2005022918 @default.
- W4385419989 hasRelatedWork W2010592884 @default.
- W4385419989 hasRelatedWork W2094714860 @default.
- W4385419989 hasRelatedWork W2373096389 @default.
- W4385419989 hasRelatedWork W2391091442 @default.
- W4385419989 hasRelatedWork W2394330061 @default.
- W4385419989 hasRelatedWork W2466043692 @default.
- W4385419989 hasRelatedWork W2470410461 @default.
- W4385419989 hasRelatedWork W4221070417 @default.
- W4385419989 isParatext "false" @default.
- W4385419989 isRetracted "false" @default.
- W4385419989 workType "article" @default.